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Poster Session II S365animals with cGVHD, with the CD4+ population having a 13-
fold reduction compared to syngeneic controls. By cell surface
phenotype, the recent thymic emigrant (RTE) CD4 proportion
(CD4+ CD44lo CCR7+ CD69-) was most severely affected, dem-
onstrating a 100-fold reduction. The spleens of affected animals
were enriched for memory T cells, particularly T effector mem-
ory (CD4+ or CD8+ CD44 high CCR7-). Furthermore, the ef-
fector memory T splenocytes of mice with cGHVD were more
likely to have an activated phenotype as evidenced by CD69 ex-
pression. Congenic AHSCT confirmed that the splenic CD4+
compartment was donor-derived. The total number of splenic
T regulatory cells (CD4hi Foxp3+ CD25+) was diminished in an-
imals with cGVHD; however, the proportion of this subset was
increased in the cGVHD mice. The T reg compartment was
also donor peripherally derived. These data show that cGVHD
is associated with impaired thymopoiesis. The relative CD4 lym-
phopenia and diminished RTE numbers likely stem from im-
paired thymic output and are associated with donor-derived
peripherally expanded CD4+ cell predominance.436
CD28-DIRECTED T CELL COSTIMULATION BLOCKADE WITH ABATACEPT
TO PREVENT GVHD DURING HIGH-RISK UNRELATED HSCT: A FIRST-IN-
DISEASE TRIAL
Kean, L.S.1, Langston, A.2, Qayed, M.1, Khoury, J.2, Tiwari, D.1,
Couture, C.1, Renfroe, H.2, Sen, S.1, Robertson, J.1, Waller, E.K.2,
Horan, J.1 1Emory University School of Medicine, Atlanta, GA; 2Emory
University School of Medicine, Atlanta, GA
We describe a first-in-disease trial of CD28-directed costimu-
lation blockade to prevent GvHD after URD HSCT in patients
.12y with advanced heme malignancies (Clinical Trials.Org
#NCT01012492). In this trial, 10 mg/kg abatacept is adminis-
tered on d -1, +5, +14, and +28 in addition to standard GvHD
prophylaxis (cyclosporine + methotrexate). 10 of 11 planned pa-
tients have enrolled, of which 8 are evaluable for engraftment
and toxicity, and 5 are evaluable for the primary immunologic
outcome of the study: the incidence of steroid-requiring GvHD
at d+100 post-transplant. The median patient age is 46 y (17-
74 y). 5 transplants were 7/8 HLA matched and 3 were 8/8
matched. 7 of the 8 patients are currently alive and in remission.
1 patient relapsed at d+98 (and died on d+121 with refractory
AML). The other 7 patients are surviving without relapse with
a follow-up of 57-377d.
All 8 patients received the 4 scheduled abatacept doses, without in-
fusional side-effects. All patients achieved neutrophil engraftment
(median d+19) and donor engraftment (100% CD33 chimerism at
d+30). Of the five post- d+100 patients, all demonstrated rapid lym-
phocyte engraftment (mean ALC.500 cells/mL by d+21). At d+100,
their mean CD3+, CD8+ and CD4+ T cell counts were 673 +/- 251,
384 +/- 148, and 229 +/- 119 cells/mL, respectively. T cell reconsti-
tution was accompanied by a shift toward a CCR7-/CD45RA- effec-
tor memory (Tem) phenotype, with CD4+ Tem increasing from 22
+/- 6% pre-transplant to 46 +/- 7%, and CD8+Tem increasing from
15 +/- 4% pre-transplant to 32 +/- 7%, both with a reciprocal de-
crease in Tnaive cells.
At the d+100 primary end-point, only 1 of the 5 evaluable patients
on the abatacept trial developed steroid-requiring GvHD. 3 addi-
tional patients are \100 days post-transplant (between d+57-64),
and none has developed GvHD. In striking contrast, in a contempo-
raneously transplanted cohort of 5 patients enrolled on an immune
monitoring protocol (and who had the same disease indications
and transplant preparative regimens, but who received standard
GvHD prophylaxis), 4 of 5 of these patients developed steroid-re-
quiring GvHD before d+100. 2 patients required salvage therapy
and one patient died from GvHD.
These preliminary data suggest that abatacept can be safely added
to cyclosporine and methotrexate for GVHD prophylaxis during
URD HSCT, with encouraging rates of GVHD at the d+100 pri-
mary endpoint. As such, they support the conduct of a larger, ran-
domized phase 2 study.437
NILOTINIB (TASIGNA) THERAPY POST ALLOGENEIC STEM CELL TRANS-
PLANTATION (ALLoSCT) FOR ADVANCED (.CP1) CHRONIC MYELOID
LEUKEMIA (CML) AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Nagler, A., Volchek, Y., Varda-Bloom, N., Somech, R., Yerushalmi, R.,
Shimoni, A. Chaim Sheba Medical Center, Ramat Gan, Israel
Relapse rate post alloSCT in advanced CML (.CP1) and in Ph+
ALL is high. We assessed (study CAN107AIL03T) whether Niloti-
nib administration post alloSCT intensifies remission and reduce re-
lapses. 24 pts (M-13, F-11), age 36 years (range, 18-58) participated
in the study. 17 pts were with advanced CML (BC-10, AP-7) and 7
with Ph+ ALL. 22/24 pts underwent alloSCT (2 are pending) from
an HLA-matched sibling (n5 11), matched unrelated (n 5 8) or al-
ternative donor (CB-2, Haplo-1). All, but one, had myeloablative
conditioning (Bu/Cy or Flu/Bu-14, TBI/Cy-7). GVHD prophylaxis
includedCSA andmethotrexate orMMF. 21/22 pts engrafted inme-
dian day+13 (range, 9-38) with 100% donor chimerism. TRT in-
cluded mucositis in all pts, encephalitis-2, pericarditis-1, VOD-1
and infection-3. 3 pts died very early post transplant from sepsis
and multi organ failure. Acute GVHD $ Gr II was observed in 10
pts (III-IV in 5). cGVHD was observed in 15 pts (extensive – 9).
16/22 transplanted pts received Nilotinib (200mg x 2/d – 10,
300mg x 2/d – 6) starting at median day +38 (range, 30-158) post al-
loSCT. 6 pts did not receive Nilotinib post alloSCT due to early
death -3, progressive disease -1, severe pancytopenia -1, refusal -1.
Nilotinib administration was delayed or dose reduced/stopped in 9
and 7 pts, respectively due to toxicities. All, but 2 pts achieved
MMR post alloSCT and 6 of them (CML) converted to CMR fol-
lowing Nilotinib therapy. Kinas mutation (G205E and F359V)
were detected only in 1 pt with disease progression. With a median
follow up of 16.5 mo (range, 2.5-38) 12 pts are alive while 12 died
(Infection -5, GVHD -3, TTP-1, disease progression -3). In 2 pts
disease progressed but responded to further therapy. All 6 pts that
did not receive Nilotinib died (early death post allo-SCT -3, disease
progression -1, GVHD Gr IV -2). Immunological evaluation post
Nilotinib administration disclosed no significant change in T, B
andNK cell numbers and T cell mitogenic response. Thymic output
(TREC) and receptor repertoire (Spectrotyping) analysis indicates
continuous thymopoiesis in 8/13 evaluated pts. NK cytotoxic activity
against K562 increased in 9/15 evaluated pts. In conclusion, post al-
loSCT Nilotinib maintenance therapy in extremely high risk pts
with advanced CML and Ph+ ALL may prevent relapse and disease
progressionand should be recommend as 1) pts achievedMMR and 6
converted to CMR with Nilotinib therapy and 2) only 5/16 pts that
received Nilotinib post alloSCT progressed.438
ALEMTUZUMAB FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE IN PEDIATRIC PATIENTS: A RETROSPECTIVE REVIEW OF 12 PA-
TIENTS REVEALS A RESPONSE RATE OF 83%
Khandelwal, P., Filipovich, A.H., Mehta, P., Jodele, S., Grimley, M.S.,
Myers, K., Jordan, M.B., Kumar, A., Bleesing, J.J., Davies, S.M.,
Marsh, R.A. Cincinnati Children’s Hospital, Cincinnati, OH
High dose steroids are themainstay of treatment of acute graft ver-
sus host disease (GVHD) with a response rate of 30-70%. A clear
second line agent for steroid refractory graft versus host disease
has not been established and it remains a significant cause of morbid-
ity and mortality in allogeneic hematopoietic cell transplant (HCT)
recipients. In order to estimate the effectiveness of alemtuzumab for
the treatment of steroid refractory acute GVHD in pediatric pa-
tients, we retrospectively reviewed the charts of 12 patients (median
age 6.5years, range 1.25-21years) with grades II (n 5 1), III (n5 6),
or IV (n 5 5) steroid refractory acute GVHD who received alemtu-
zumab for treatment. Steroid refractory acute GVHDwas defined as
progression of GVHD after 48 hours of./5 2 mg/kg steroid treat-
ment, or lack of response within 5 days. Patients received a median
dose of 0.73mg/kg alemtuzumab (range 0.3-2mg/kg) divided over
2-5 days. Seventy-five percent of patients received repeated courses.
A complete response, defined asGVHDof grade 0 at 4 weeks follow-
ing the first alemtuzumab course, was observed in 7 patients (58%). A
partial response, defined as a grade improvement after 4 weeks, was
S366 Poster Session IIobserved in 3 patients (25%). There was no response in 2 patients
(16%). The overall response rate at 4 weeks was 83%. Infectious
complications were common, including bacteremia (41%), adenovi-
rus viremia (50%), and CMV viremia (33%). Relapse of acute
GVHD was observed in 42% of complete responders. Fifty percent
of patients are currently surviving at a median follow up time of 775
days following first alemtuzumab course. We conclude that alemtu-
zumab is an effective treatment for steroid refractory GVHD in pe-
diatric patients with a tolerable spectrum of complications. The
dose, timing, and length of treatment should be optimized in a pro-
spective study.439
THERAPY OF STEROID-REFRACTORY CHRONIC GVHD WITH SUBCUTA-
NEOUS LOW-DOSE ALEMTUZUMAB AND RITUXIMAB COMBINATION IS
EFFECTIVE AND SAFE
Gutierrez-Aguirre, C.H., Cantu-Rodriguez, O.G., Gonzalez-Llano, O.,
Jaime-Perez, J.C., Mancias-Guerra, C., Flores-Jimenez, J.A., Ala-
torre-Ricardo, J., Gomez-Almaguer, D. Hospital Universitario ‘‘Dr.
Jose E. Gonzalez’’, Monterrey, Nuevo Leon, Mexico
Introduction:Chronic graft-versus-host disease (cGVHD) is a com-
mon late complication of allogeneic hematopoietic stem cell trans-
plantation. Corticosteroids with or without a calcineurin inhibitor
are the standard treatment for cGVHD. A second-line treatment is
not well defined. A simultaneous reduction of both B and T-cells
might be an efficacious treatment strategy for cGVHD, gaining
a strict control of the immune system responsible of pathophisiology
of cGVHD.We evaluated the effectiveness and safety of low doses of
alemtuzumab and rituximab as treatment for steroid-refractory
cGVHD.
Methods:Tenmen and 5 womenwere included. All patients had re-
ceived an identical-HLA allo-RIC peripheral stem cell transplant
and had cGVHD refractory to steroids and CSA according to
NIH criteria’s. The median age was 41 years old. The main site in-
volved was the oral mucosa (87%) followed by the eyes (67%), liver
(60%), skin (53%), lungs (13%) and intestinal tract (7%). All patients
received subcutaneous Alemtuzumab 10 mg on days +1 to +3 and in-
travenous Rituximab 100 mg on days +4, +11, +18 and +25.
The therapeutic response was measured on days +30, +90 and
+365 of the protocol.
Results: The overall response was 100% at +30-day evaluation, 10
patients had partial remission (PR) and 5 patients had complete re-
mission (CR). At +90-day evaluation, 7 patients had PR, 4 CR, 3
had cGVHD relapsed and 1 patient had not yet reached 90 days.
Currently, 5 patients have reached the +365-day follow-up evalua-
tion, 2 (40%) had PR, 2 had CR and 1 showed cGVHD progression.
The adverse effects were mainly infection in 60%of patients, quickly
solved in all cases, except one patient who died from pneumonia.
Conclusion: Low dose alemtuzumab-rituximab combination ther-
apy appears to be an efficacious and safe treatment for steroid-refrac-
tory cGVHD. Longer follow-up is necessary in this study in order to
determine the durability of response and survival.440
DECODING OF THE GENOME WIDE microRNA-mRNA INTERACTION
MAPS WITH HITS-CLIP REVEALS A DISTINCT miRNAOME IN allo-
ANTIGEN ACTIVATED T CELLS
Sun, Y., Toubai, T., Nieves, E., Iyer, M., Tawara, I., Reddy, P. University
of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Following allogeneic bone marrow transplantation (BMT), donor
T cells that respond to allo-antigens cause GVHD and those that re-
spond to non-alloantigens are critical for immune-reconstitution. A
genome wide molecular landscape of the T cells responding to allo-
antigens and the non-alloantigens and whether they are distinct is
not known.
MicroRNAs (miRs) are critical molecular regulators; miR ac-
tivity requires base pairing with messenger RNA (mRNA). But
predicting target mRNAs is a challenge. High-throughput se-quencing of RNAs isolated by crosslinking immunoprecipitation
(HITS-CLIP) identifies functional protein-RNA interaction sites.
We mapped genome-wide protein-RNA binding sites to cova-
lently crosslink native argonaute (Ago) protein-RNA complexes
in alloantigen activated and non-alloatigen, CD3+antibody acti-
vated T cells. Ago HITS-CLIP pulls down AGO proteins along
with miRs and associated mRNAs with subsequent application to
miR and mRNA arrays (RIP-Chips) identify clinically relevant
miR-mRNA interactions.
Forty five miRs were differentially enriched in activated T
cells, either allo-T cells or CD3-ab-stimulated T cells that
were divided into 4 groups. Amongst them, only 19 miRs were
enriched in allo-T cells when compared to CD3 antibody-treated
T cells. Six of the 19 (miR-142-3p, 142-5p, 16, 29a, 66d and
669i) were selected for further analysis, and their transcript en-
richments were screened by Affymetrix microarrays for mRNAs.
A total of only 1226 genes were expressed while 200 genes
were differentially expressed in allo-T cells and 288 genes in
CD3-ab-T cells. We next cross-linked the data from RIP-
Chip-miRs and mRNA affymetrix to target prediction programs
and hypothesized that reduced miR enrichments should be
companied with decreased mRNA enrichments. We found that
Fchsd2, Wapal and MLL3 genes were predicted to be targets
of miR-16, Cyb5r3 as miR-142-3p target, Rcor1 as miR-29a,
Synji1 and Med17 as miR-142-5p, LPP as miR-669d, Dock9 as
miR-660i and Rcor1 as target of miR-669i respectively.
Validation studies with RT-qPCR and western blot confirmed the
patterns of enrichment of the miRs -16, 142-3p, 142-5p and 29a and
the predicted targets Wapal and Fchsd2. This pattern was also con-
firmed in vivo following BALB/c into B6 BMT.
In summary, we demonstrate for the first time distinct miR-
mRNA interactionmap based on genomewide analysis with the state
of art HITS-CLIP and identified specific targets in allo-activated T
cells.441
TCR TRANSDUCTION APPROACH TO EXPAND SEVERE GRAFT-VERSUS-
HOST DISEASE INDUCING CD4 SPECIFIC T CELLS
Matos, J., Appel, M., Korngold, R., Friedman, T. Hackensack University
Medical Center, Hackensack, NJ
Allogeneic hematopoietic cell transplantation (HCT) remains the
most promising curative therapy for the treatment of hematological
malignancies, but is complicated by the development of graft-versus-
host disease (GVHD), mediated by donor T cells targeted against ei-
ther HLA or minor histocompatibility antigens (miHA) of the host.
CD4 T cells recognizing certain miHA have been found capable of
mediating severe GVHD on their own in some murine models. Pre-
vious studies have utilized CDR3-size spectratyping to identify
a unique population of CD4+Vb11+ T cells that have subsequently
been shown capable of infiltrating both the rete-like prominences
of the dorsal lingual epithelium and the ileal crypts of the small in-
testine while mediating lethal GVHD in the miHA disparate
C57BL/6 (B6) / C.B10-H2b/LiMcdJ (BALB.B) transplantation
model. The unique and restricted BALB.B specific T cell response
of the B6 CD4+ Vb11+ T cells indicates a limited number of
miHA are likely responsible for the lethal GVHD observed. Se-
quencing of the skewed bands from CD4+ Vb11+spectratype analy-
sis of BALB.B recipients with GVHD indicated a strong prevalence
(65%) of the T cell receptor (TCR) Jb 2.5, implying a dominant al-
loreactive expansion within this specific CD4+ Vb11+ T cell family.
However, a better understanding of the pathogenesis of this partic-
ular response has been hampered by the insufficient quantity of T
cells expressing the specific miHA-reactive TCR. To facilitate fur-
ther study of this CD4 response, we have utilized TCR transduction
of bone marrow from B6.129P2-Tcrbtm1Mom/J TCR b-chain
knockout mice (TCR b -/-) mice with GFP-tagged DNA sequence,
which we then transplanted back into lethally irradiated TCRb -/-
mice to generate an efficient source of large numbers of this minute
population of reactive, GVHD-associated Vb11+ T cells. We con-
clude that TCR transduction can be utilized to generate large num-
bers of highly specific, reactive T cell populations for use during in
vitro or in vivo experiments to characterize previously inaccessible
populations of GVHD mediating T cells.
